Abstract
Abrocitinib, a once-daily oral Janus kinase 1 selective inhibitor, has shown efficacy and safety in previous studies for treating moderate-to-severe atopic dermatitis (AD). Abrocitinib is primarily eliminated via the liver, but its major circulating metabolites are eliminated mainly by renal excretion. In this phase 1, nonrandomized, open-label, single-dose (200 mg) study (NCT03660241), we evaluated the impact of renal impairment on the pharmacokinetics, safety, and tolerability of abrocitinib and its metabolites in 23 subjects with different degrees of renal function (ie, normal renal function, moderate impairment, and severe impairment).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
